GE Leads EU AI Cardio-Oncology Care Consortium
Chicago, USA – March 26, 2026 GE HealthCare announced a leading industrial role in the €50.5 million COMPASS consortium,...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
Chicago, USA – March 26, 2026 GE HealthCare announced a leading industrial role in the €50.5 million COMPASS consortium,...
CHICAGO, ILLINOIS, March 23, 2026 GE HealthCare has announced that the U.S. Food and Drug Administration (FDA) has granted...
CHICAGO, Dec. 29, 2025 — GE HealthCare announced that its senior management team will present at an upcoming January...
